It's why researchers are now investigating whether GLP-1 weight loss medications, such as Ozempic (semaglutide) and Zepbound (tirzepatide), in combination with hormone replacement therapy, can help women maintain a healthy size and treat symptoms in midlife
In a clinical trial of people with Type 2 diabetes and moderate to severe kidney disease, the drug reduced the risk of kidney disease progression and cut the death rate from cardiovascular and kidney-related causes by 24 percent such a clear result that the trial was ended early
Drug-Disease Interactions: Carni Q Tablet may interact with disease conditions, including renal dysfunction and malabsorption syndrome
While these supplements work from the inside out, excessive UV exposure is the number one cause of collagen breakdown
The VCT was 30 days among severe COVID-19 patients and 39 days among ICU-admitted patients 109,110
Established risk factors for venous thromboembolism (VTE) include: Obesity (BMI 30 kg/m), which increases venous stasis and pro-inflammatory states Immobility or reduced mobility , particularly relevant in patients with severe obesity Previous history of VTE or family history of thrombophilia Active malignancy or recent surgery Hormonal therapies , including combined oral contraceptives or hormone replacement therapy Pregnancy and the postpartum period Smoking , which affects endothelial function and coagulation Risk factors for arterial thrombosis (myocardial infarction, stroke) include: Type 2 diabetes mellitus , associated with endothelial dysfunction, platelet hyperreactivity, and a prothrombotic state Hypertension , causing arterial wall damage Dyslipidaemia , promoting atherosclerotic plaque formation Established cardiovascular disease Chronic kidney disease , common in diabetes and associated with increased cardiovascular risk Patients initiating GLP-1 therapy should undergo a comprehensive cardiovascular risk assessment
